On the basis of geographical analysis, the global whooping cough treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing pediatric population, along with growing availability of healthcare facilities in the developing regions. Moreover, the high prevalence of whooping cough in countries, such as, India, China, Japan, Philippines, Vietnam, and others, is further estimated to boost the market growth. According to the data by WHO, 12,566 cases of pertussis were reported in India, while 2,947 cases were reported in Japan, in 2020. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the advanced healthcare technologies present in the region, along with the presence of major pharmaceutical companies.
The global whooping cough treatment market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global whooping cough treatment market includes the following segments:
By Patient Type
By Drug Type
May 04, 2021: Teva Pharmaceutical Industries Ltd. announced the launch of its new Erythromycin tablets to treat or prevent a variety of bacterial infections.
February 27, 2020: GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced the European Medicines Agency (EMA) approval of Trelegy Ellipta for the treatment of asthma in adults.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: The increasing prevalence of whooping cough, especially amongst children, is estimated to boost the market growth.
Ans: The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2031.
Ans: Low availability of treatment facilities, such as, medical practitioners, and vaccines, in undeveloped regions are estimated to hamper the market growth.
Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the advanced healthcare sector in the region.
Ans: The major players in the market are Pfizer Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Siemens Healthcare GmbH, Baxter International, Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by patient type, drug type, end-user, and by region.
Ans: The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.